Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

September 30, 2011 | Corporate News | English

Tecan issues update on an OEM development project

  • Project developments resulting in a delay
  • Additional costs could place burden on future operating profit in low to mid-single digit range in CHF millions
  • No impact to operating profit in 2011 and 2012
  • Tecan continues to anticipate total sales potential of more than CHF 80 million in the first five years following successful development


Männedorf, Switzerland, September 30, 2011 – The Tecan Group (SIX Swiss Exchange: TECN) today issued an update regarding an OEM development project (project name used externally: P14) signed with a global diagnostics company in November 2010. The agreement covers the development and supply of a dedicated diagnostics instrument. Tecan had expected to ship the first instruments to the diagnostics company in late 2012. Tecan now anticipates that supply be delayed.

The November 2010 agreement also stipulates that Tecan will pre-finance the instrument’s development costs and these will then be repaid at a later stage. However, the agreement does not cover any additional costs arising as a result of project delays. Following the commencement of supplies in 2013 and for the ten-year term of the agreement, Tecan anticipates that its share of the development costs could place an annual burden on operating profit in the low to mid-single digit range in CHF millions. This event will not affect operating profit in 2011 and 2012.

Tecan remains convinced of the OEM agreement’s great potential and continues to anticipate total sales potential of more than CHF 80 million in the first five years of marketing following successful development. This expectation is reinforced by the minimum purchase commitment the diagnostics company has entered into.


About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2010, Tecan generated sales of CHF 371 million (USD 356 million; EUR 269 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).



For further information
Tecan Group

Dr. Rudolf Eugster                 Martin Braendle
Chief Financial Officer   Head of Corporate Communications &
Investor Relations
investor@tecan.com   Tel. +41 (0) 44 922 84 30
www.tecan.com   Fax +41 (0) 44 922 88 89